Incomplete Freund's adjuvant
Showing 1 - 25 of 5,537
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma Trial in Buffalo, Rochester (biological,
Active, not recruiting
- Partial Response of Multiple Myeloma or Plasma Cell Leukemia
- Plasma Cell Myeloma
- Incomplete Freund's Adjuvant
- +4 more
-
Buffalo, New York
- +1 more
Dec 12, 2022
Melanoma (Skin) Trial in Philadelphia, Houston, Charlottesville (incomplete Freund's adjuvant, melanoma helper peptide vaccine,
Completed
- Melanoma (Skin)
- incomplete Freund's adjuvant
- +4 more
-
Philadelphia, Pennsylvania
- +2 more
Mar 25, 2021
Multiple Sclerosis Trial in San Diego (NeuroVax, IFA Incomplete Freund's Adjuvant)
Unknown status
- Multiple Sclerosis
- NeuroVax
- IFA Incomplete Freund's Adjuvant
-
San Diego, CaliforniaCRO
Mar 9, 2020
Melanoma (Skin) Trial in Charlottesville (biological, drug, procedure)
Completed
- Melanoma (Skin)
- incomplete Freund's adjuvant
- +6 more
-
Charlottesville, VirginiaUniversity of Virginia Cancer Center
Mar 26, 2020
Multiple Sclerosis Trial in San Diego (NeuroVax, IFA Incomplete Freund's Adjuvant)
Not yet recruiting
- Multiple Sclerosis
- NeuroVax
- IFA Incomplete Freund's Adjuvant
-
San Diego, CaliforniaCRO
Mar 30, 2020
Breast Cancer Trial in Philadelphia (incomplete Freund's adjuvant, sargramostim, telomerase: 540-548 peptide vaccine)
Completed
- Breast Cancer
- incomplete Freund's adjuvant
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Feb 3, 2020
Prostate Cancer Trial (PSA prostate cancer vaccine, incomplete Freund's adjuvant)
Completed
- Prostate Cancer
- PSA prostate cancer vaccine
- incomplete Freund's adjuvant
- (no location specified)
Oct 31, 2019
HIV Trial (HIV-1 Immunogen, Structured Treatment Interruption)
Withdrawn
- HIV Infections
- HIV-1 Immunogen
- Structured Treatment Interruption
- (no location specified)
Oct 28, 2021
Thymoma and Thymic Carcinoma Trial in Shanghai (Cisplatin, Etoposide, radiotherapy)
Recruiting
- Thymoma and Thymic Carcinoma
- Cisplatin
- +2 more
-
Shanghai, Shanghai, ChinaKailiang Wu
Feb 5, 2020
Secondary Progress Multiple Sclerosis, Multiple Sclerosis Trial in San Diego (NeuroVax, IFA Placebo)
Recruiting
- Secondary Progress Multiple Sclerosis
- Multiple Sclerosis
- NeuroVax
- IFA Placebo
-
San Diego, CaliforniaCRO
Mar 9, 2020
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma Trial in United States
Recruiting
- Advanced Colorectal Carcinoma
- +42 more
- Elimusertib
- +3 more
-
Duarte, California
- +9 more
Jan 21, 2023
HIV Trial in United States (ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen)
Completed
- HIV Infections
- ALVAC(2)120(B,MN)GNP (vCP1452)
- HIV-1 Immunogen
-
Los Angeles, California
- +16 more
Oct 28, 2021
Breast Cancer Trial in Scottsdale, Jacksonville, Rochester (CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide
Completed
- Breast Cancer
- CpG oligodeoxynucleotide
- +6 more
-
Scottsdale, Arizona
- +2 more
Oct 29, 2018
Tumors, Esophageal Tumors, Esophagus Tumor Trial run by the National Cancer Institute (NCI) (Nivolumab, Entinostat, Montanide(R)
Not yet recruiting
- Neoplasms
- +5 more
- Nivolumab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 16, 2023
Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)
Not yet recruiting
- Stage IIIB(N2) Non-small Cell Lung Cancer
- +3 more
- Pembrolizumab 200 mg IV infusion
-
Beijing, Beijing, ChinaPeking University
May 30, 2023
Bladder Cancer Trial in Aarhus (Mitomycin c)
Active, not recruiting
- Bladder Cancer
- Mitomycin c
-
Aarhus, DenmarkAarhus University Hospital
Aug 5, 2022
Periodontitis Trial in Rohtak (Scaling and root planing with antibiotics, Scaling and root planing only)
Completed
- Periodontitis
- Scaling and root planing with antibiotics
- Scaling and root planing only
-
Rohtak, Haryana, IndiaSanjay Tewari
Dec 22, 2022
NSCLC NSCLC Trial in Switzerland (MEDI4736 (anti-PD-L1))
Active, not recruiting
- NSCLC Non-small Cell Lung Cancer
- MEDI4736 (anti-PD-L1)
-
Zürich, Zurich, Switzerland
- +18 more
Jan 20, 2022
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma Trial in United States (Laboratory Biomarker
Completed
- Iris Melanoma
- +19 more
- Laboratory Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +147 more
Jun 24, 2020
Primary Biliary Cholangitis Trial in United States (Seladelpar 10 mg, Placebo)
Recruiting
- Primary Biliary Cholangitis
- Seladelpar 10 mg
- Placebo
-
Chandler, Arizona
- +3 more
Oct 2, 2023
Soft Tissue Sarcoma Trial in France (Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior
Not yet recruiting
- Soft Tissue Sarcoma
- Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.
- Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).
-
Bordeaux, France
- +10 more
Aug 28, 2023
Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)
Not yet recruiting
- Endometrial Carcinoma
-
Sohag, EgyptSohag university Hospital
Oct 25, 2023
Impact of Incomplete Endometrial Ablation
Enrolling by invitation
- Heavy Menstrual Bleeding
- hysteroscopy
-
Veldhoven, Noord-Brabant, NetherlandsMáxima MC
Nov 5, 2023
Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone hydrochloride liposome injection
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Aug 15, 2023
Shigellosis, Bacillary Dysentery Trial in Leiden (2.5 µg InvaplexAR-Detox, 10 µg InvaplexAR-Detox, 0.1 µg of dmLT)
Not yet recruiting
- Shigellosis
- Bacillary Dysentery
- 2.5 μg InvaplexAR-Detox
- +3 more
-
Leiden, NetherlandsLeiden University Medical Center
Jul 26, 2023